RxDoctor Payments Data

Philip Creps, DO

Psychiatry · Gardena, CANPI 1649284688

Payments from drug & device makers

$4,116in general payments, 2019–2025

Across 152 payments — averaging $27.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$593
  • Otsuka America Pharmaceutical, Inc.$549
  • Johnson & Johnson$358
  • Almatica Pharma LLC$305
  • Lundbeck LLC$256
  • plus $859 from 14 others

What the payments were for

  • Consulting fees$2005%
  • Food & beverage$3,85494%
  • Education$622%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,116 in reported general payments places this provider in the 85th percentile of 4,954 psychiatry providers in California.

See all psychiatry providers in California

Medicare billing

Part B allowed, 2024
$57,022
Medicare patients
14
Services billed
141

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide12$11,689
Rivastigmine13$4,073
Duloxetine Hcl35$1,295
Trazodone Hcl45$449
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine16$353
Fluoxetine Hcl24$345
Bupropion XlBupropion Hcl15$301
Sertraline Hcl27$213
Mirtazapine14$213
Propranolol Hcl12$175
Alprazolam19$152
Quetiapine Fumarate20$129
Clonazepam33$129
Zolpidem Tartrate17$83
Lorazepam17$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$305$21327 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,954 psychiatry providers in California.

Other psychiatry in Gardena

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →